TABLE 4.
Bacteriologic success at follow-up for individual pathogens in microbiologically evaluable patients treated with grepafloxacin (400 or 600 mg once daily) or ciprofloxacin (500 mg twice daily)
| Pretreatment pathogen | No. of pathogens successfully treated/total no. of pathogens (%)
|
||
|---|---|---|---|
| Grepafloxacin at 400 mg once daily | Grepafloxacin at 600 mg once daily | Ciprofloxacin at 500 mg twice daily | |
| H. influenzae | 17/19a (90) | 15/16 (94) | 15/18 (83) |
| β-Lactamase negative | 10/11 (91) | 11/11 (100) | 12/12 (100) |
| β-Lactamase positive | 7/7 (100) | 4/5 (80) | 3/6 (50) |
| H. parainfluenzae | 4/4 (100) | 4/4 (100) | 5/5 (100) |
| M. catarrhalis | 18/20a (90) | 18/21 (86) | 15/16 (94) |
| β-Lactamase negative | 4/4 (100) | 1/1 (100) | 4/4 (100) |
| β-Lactamase positive | 13/15 (87) | 17/20 (85) | 11/12 (92) |
| S. aureus | 11/15 (73) | 14/17 (82) | 14/17 (82) |
| S. pneumoniae | 6/8 (75) | 7/8 (88) | 2/5 (40) |
a
One H. influenzae isolate and one M. catarrhalis isolate were not tested for β-lactamase production.